Karamperis, Kariofyllis http://orcid.org/0000-0002-3085-7799
Koromina, Maria http://orcid.org/0000-0001-8843-082X
Papantoniou, Panagiotis
Skokou, Maria http://orcid.org/0000-0002-8579-8933
Kanellakis, Filippos http://orcid.org/0000-0001-8959-0622
Mitropoulos, Konstantinos
Vozikis, Athanassios
Müller, Daniel J.
Patrinos, George P. http://orcid.org/0000-0002-0519-7776
Mitropoulou, Christina http://orcid.org/0000-0002-9184-4668
Funding for this research was provided by:
European Commission (H2020-668353)
Article History
Received: 5 December 2020
Revised: 8 June 2021
Accepted: 17 June 2021
First Online: 2 July 2021
Competing interests
: The authors declare no competing interests. GPP is Full Member and national Representative of the European Medicines Agency, Committee for Human medicinal Product (CHMP) – Pharmacogenomics Working Party (Amsterdam, the Netherlands) and member of the Clinical Pharmacogenetics Implementation Consortium (CPIC). DJM is a member of CPIC and co-investigator in two pharmacogenetic studies where genetic test kits were provided as in-kind contribution by Myriad Neuroscience. No payment or any equity, stocks, or options from any pharmacogenetic testing company was obtained.